论文部分内容阅读
目的:观察低分子肝素联合尿激酶治疗原发性肾病综合征的疗效。方法:将42例原性性肾病综合征合并高凝状态的患者在内科基础上予以低分子肝素钙和尿激酶治疗,并进行分析。结果:治疗后24 h尿蛋白定量、血浆白蛋白、总胆固醇、凝血酶原时间(PT)、部分凝血酶原时间(APTT)、纤维蛋白原(FDP)均有不同程度好转。结论:低分子肝素钙联合尿激酶治疗肾病综合征有助于降低蛋白尿,缩短病程,并有保护肾脏作用,该治疗方法不良反应小,患者能耐受。
Objective: To observe the effect of low molecular weight heparin combined with urokinase in the treatment of primary nephrotic syndrome. Methods: 42 patients with nephrotic syndrome complicated with hypercoagulable state were treated with low molecular weight heparin and urokinase on the basis of internal medicine and analyzed. Results: Urinary protein, serum albumin, total cholesterol, prothrombin time (PT), partial prothrombin time (APTT) and fibrinogen (FDP) were all improved in 24 h after treatment. Conclusion: The treatment of nephrotic syndrome with low molecular weight heparin combined with urokinase can reduce proteinuria, shorten the course of disease and protect the kidneys. The adverse reactions of this treatment are small and patients can tolerate.